Quantcast

Stonepine Capital Management, LLC Buys Recro Pharma, SciClone Pharmaceuticals, Novelion ...


Shutterstock photo
Stonepine Capital Management, LLC
  • New Purchases: SCLN , NVLN , OPHT , ENTA, VCYT, BDSI, SCMP, TRIB, MNK,
  • Added Positions:REPH, CRME, ALIM, ALR, VCEL, CPIX, DRRX, JNP,
  • Reduced Positions:CUTR, AVIR,
  • Sold Out:TBRA, DSCI, PCRX,

For the details of Stonepine Capital Management, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Stonepine+Capital+Management%2C+LLC

These are the top 5 holdings of Stonepine Capital Management, LLC

  1. Recro Pharma Inc ( REPH ) - 2,874,317 shares, 15.85% of the total portfolio. Shares added by 145.54%
  2. Alere Inc ( ALR ) - 360,000 shares, 9.6% of the total portfolio. Shares added by 25.59%
  3. SciClone Pharmaceuticals Inc ( SCLN ) - 1,249,200 shares, 9.23% of the total portfolio. New Position
  4. Viveve Medical Inc ( VIVE ) - 2,599,711 shares, 9.1% of the total portfolio.
  5. Novelion Therapeutics Inc ( NVLN ) - 1,524,034 shares, 8.78% of the total portfolio. New Position


New Purchase: SciClone Pharmaceuticals Inc ( SCLN )

Stonepine Capital Management, LLC initiated holdings in SciClone Pharmaceuticals Inc. The purchase prices were between $8.65 and $10.8, with an estimated average price of $10. The stock is now traded at around $9.40. The impact to the portfolio due to this purchase was 9.23%. The holdings were 1,249,200 shares as of 2016-12-31.

New Purchase: Novelion Therapeutics Inc ( NVLN )

Stonepine Capital Management, LLC initiated holdings in Novelion Therapeutics Inc. The purchase prices were between $7.9 and $10.5, with an estimated average price of $9.11. The stock is now traded at around $10.69. The impact to the portfolio due to this purchase was 8.78%. The holdings were 1,524,034 shares as of 2016-12-31.

New Purchase: Ophthotech Corp (OPHT)

Stonepine Capital Management, LLC initiated holdings in Ophthotech Corp. The purchase prices were between $4.82 and $45.3, with an estimated average price of $29.68. The stock is now traded at around $3.35. The impact to the portfolio due to this purchase was 7.58%. The holdings were 2,292,900 shares as of 2016-12-31.

New Purchase: Enanta Pharmaceuticals Inc (ENTA)

Stonepine Capital Management, LLC initiated holdings in Enanta Pharmaceuticals Inc. The purchase prices were between $22.32 and $34.53, with an estimated average price of $28.66. The stock is now traded at around $28.50. The impact to the portfolio due to this purchase was 5.31%. The holdings were 231,913 shares as of 2016-12-31.

New Purchase: Veracyte Inc (VCYT)

Stonepine Capital Management, LLC initiated holdings in Veracyte Inc. The purchase prices were between $6.12 and $8.14, with an estimated average price of $7.48. The stock is now traded at around $9.04. The impact to the portfolio due to this purchase was 5.14%. The holdings were 970,500 shares as of 2016-12-31.

New Purchase: BioDelivery Sciences International Inc (BDSI)

Stonepine Capital Management, LLC initiated holdings in BioDelivery Sciences International Inc. The purchase prices were between $1.6 and $2.64, with an estimated average price of $2.04. The stock is now traded at around $1.90. The impact to the portfolio due to this purchase was 3.11%. The holdings were 2,600,711 shares as of 2016-12-31.

Added: Recro Pharma Inc ( REPH )

Stonepine Capital Management, LLC added to the holdings in Recro Pharma Inc by 145.54%. The purchase prices were between $6.22 and $9.3, with an estimated average price of $7.63. The stock is now traded at around $7.64. The impact to the portfolio due to this purchase was 9.39%. The holdings were 2,874,317 shares as of 2016-12-31.

Added: Cardiome Pharma Corp (CRME)

Stonepine Capital Management, LLC added to the holdings in Cardiome Pharma Corp by 64.63%. The purchase prices were between $2.55 and $3.17, with an estimated average price of $2.86. The stock is now traded at around $3.03. The impact to the portfolio due to this purchase was 2.34%. The holdings were 3,158,816 shares as of 2016-12-31.

Added: Alimera Sciences Inc (ALIM)

Stonepine Capital Management, LLC added to the holdings in Alimera Sciences Inc by 142.02%. The purchase prices were between $1.06 and $1.52, with an estimated average price of $1.22. The stock is now traded at around $1.39. The impact to the portfolio due to this purchase was 2%. The holdings were 4,615,813 shares as of 2016-12-31.

Added: Alere Inc ( ALR )

Stonepine Capital Management, LLC added to the holdings in Alere Inc by 25.59%. The purchase prices were between $34.83 and $45.09, with an estimated average price of $40.38. The stock is now traded at around $38.27. The impact to the portfolio due to this purchase was 1.96%. The holdings were 360,000 shares as of 2016-12-31.

Added: Vericel Corp (VCEL)

Stonepine Capital Management, LLC added to the holdings in Vericel Corp by 84.14%. The purchase prices were between $2.05 and $4.1, with an estimated average price of $2.57. The stock is now traded at around $2.75. The impact to the portfolio due to this purchase was 1.77%. The holdings were 1,883,800 shares as of 2016-12-31.

Added: Cumberland Pharmaceuticals Inc (CPIX)

Stonepine Capital Management, LLC added to the holdings in Cumberland Pharmaceuticals Inc by 91.36%. The purchase prices were between $4.7 and $5.72, with an estimated average price of $5.22. The stock is now traded at around $6.32. The impact to the portfolio due to this purchase was 1.11%. The holdings were 619,538 shares as of 2016-12-31.

Sold Out: Tobira Therapeutics Inc (TBRA)

Stonepine Capital Management, LLC sold out the holdings in Tobira Therapeutics Inc. The sale prices were between $39.51 and $42.09, with an estimated average price of $40.62.

Sold Out: Derma Sciences Inc (DSCI)

Stonepine Capital Management, LLC sold out the holdings in Derma Sciences Inc. The sale prices were between $4.25 and $5.6, with an estimated average price of $4.7.

Sold Out: Pacira Pharmaceuticals Inc (PCRX)

Stonepine Capital Management, LLC sold out the holdings in Pacira Pharmaceuticals Inc. The sale prices were between $30.25 and $37.6, with an estimated average price of $33.37.



Premium Members

This article first appeared on GuruFocus .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Stocks
Referenced Symbols: REPH , VIVE , NVLN



More from GuruFocus

Subscribe






GuruFocus
Contributor:

GuruFocus

Stock Picks, Portfolios










Research Brokers before you trade

Want to trade FX?